This Molecular Tumor Board, our Oncology Medical Affairs team reviews concurrent tissue- and plasma-based comprehensive NGS testing for the management of a young patient with advanced stage NSCLC. A growing number of guideline-recommended biomarkers are reviewed for frontline targeted therapy selection and prevalence of oncogenic driver alterations in NSCLC. The process of utilizing and optimizing cytology specimens for NGS analysis is also discussed.